It is noteworthy that KRAS overexpression confers an adverse prognosis in cytogenetically normal acute myeloid leukemia (AML) [43] and somatic activation of oncogenic KRAS in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder [44]. This evidence concerns the gene KRAS and myeloproliferative disorder.